Bacopa
Bacopa monnieri · Brahmi (Ayurvedic) · Water Hyssop
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
A 3 (mixed/moderate RCT) is the honest grade for the one use the evidence actually supports, which is a modest gain in memory retention and speed of attention in adults after roughly twelve weeks of a standardized extract. Several small double-blind placebo-controlled trials point the same direction. Stough 2001 (Psychopharmacology, 46 healthy adults, 300 mg/day of the CDRI-08 extract standardized to 55 percent bacosides) reported improved verbal learning, memory consolidation, and speed of early information processing at week 12. Roodenrys 2002 (Neuropsychopharmacology, 76 adults aged 40 to 65) found that Brahmi slowed the rate of forgetting of newly learned information rather than speeding acquisition. Calabrese 2008 (Journal of Alternative and Complementary Medicine, 54 adults 65 and older, 300 mg/day) found lower anxiety and depression scores but no benefit on several cognitive measures, showing the effect is not universal. The Kongkeaw 2014 meta-analysis (Journal of Ethnopharmacology, 9 RCTs, 518 participants, 250 to 450 mg/day for 12 weeks or more) concluded the extract improved reaction time and attention with a signal toward memory. The Pase 2012 systematic review was more cautious, finding improvement on only 9 of 17 free-recall memory tests and little evidence in other cognitive domains, with no two trials using the same assessment. The effect is real but small, the trials are small, and the trials use non-interchangeable extracts and outcome measures, which is why this sits at 3 rather than 4. It stays clear of the marketed halo of dementia treatment, where human evidence is thin.
- FDA
- Legal supplement (DSHEA)
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Generally well tolerated; gastrointestinal upset is the usual complaint (take with food), with thyroid, cholinergic, and CYP450 interaction cautions, pregnancy data lacking, and a real risk of species mislabeling versus gotu kola.
Bacopa monnieri is a creeping wetland herb long used in Ayurvedic medicine, where it is called Brahmi and grouped among the Medhya Rasayana, the herbs said to support intellect and memory. Its saponin compounds, the bacosides, are the presumed actives. Among traditional nootropic herbs it carries an unusually real modern trial record, and the honest headline is a modest one: standardized extract at around 300 mg a day appears to improve memory retention and attention speed in adults, but only after about twelve weeks of daily use. That delayed onset sets up a common expectation mismatch, since people expect a same-day lift and get none. Mild gastrointestinal upset is the most frequent complaint, especially on an empty stomach.
The Ayurvedic Medhya Rasayana with substantial modern cognitive RCT inheritance, slow-onset, real-effect.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Bacopa monnieri is a creeping aquatic herb of the Plantaginaceae family (formerly Scrophulariaceae) growing in wetlands across India, Southeast Asia, southern China, parts of Africa, Australia, and the Americas. The Sanskrit name Brahmi (literally "belonging to Brahma" or "supreme consciousness") is applied in Ayurveda primarily to Bacopa monnieri, though the same name is also used for Centella asiatica (gotu kola) in some Ayurvedic traditions, producing one of the more substantial naming confusions in herbal medicine. Bacopa specifically belongs to the Ayurvedic "Medhya Rasayana" category, herbs traditionally classified as cognitive enhancement and longevity tonics, with Bacopa among the most prominent members alongside Centella asiatica, Convolvulus pluricaulis (shankhapushpi), and Acorus calamus. Continuous Ayurvedic clinical use extends more than three thousand years; the herb appears in foundational Ayurvedic texts including the Charaka Samhita and Sushruta Samhita with extensive documentation of cognitive, neurological, and longevity applications. Modern phytochemistry has characterized the active compound complex as bacosides, saponin glycosides with steroidal aglycone structures. The major bacosides include bacoside A (a mixture composed primarily of bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X, the "Bacoside A complex" in commercial standardization), bacoside B, bacopasides I through XII, and various minor compounds. The KeenMind branded extract (from Pharmacist Marsh, Australia, also marketed as CDRI 08) is standardized to ≥55% combined bacosides and was used in the foundational Stough 2001 Psychopharmacology cognitive trial. BacoMind (from Natural Remedies, India) provides a different standardization profile, typically ≥45% total bacosides with more comprehensive characterization of individual bacoside content. The pharmacology centers on multiple mechanisms: cholinergic neurotransmission modulation (relevant to memory consolidation and acetylcholine pathway support, bacopa is sometimes characterized as a "natural acetylcholinesterase inhibitor" though this characterization is mechanistically more nuanced than pharmaceutical AChE inhibitors); antioxidant defense in brain tissue (bacosides reduce lipid peroxidation in animal models); neurotrophic effects through BDNF (brain-derived neurotrophic factor) upregulation; modest anxiolytic effects through serotonergic and GABAergic mechanisms; vasodilatory and cerebral blood flow effects; possible amyloid-beta interactions relevant to Alzheimer's disease research (preliminary). Clinical evidence for Bacopa is substantially stronger than most Ayurvedic herbs at modern RCT methodology, the Stough 2001, Roodenrys 2002, Calabrese 2008, and subsequent trials provide foundational evidence base. The effect-size pattern is interesting: bacopa produces measurable cognitive effects (particularly in memory consolidation, working memory, attention, and information processing speed) but with characteristically slow onset, most clinical trials show meaningful effects beginning 4-8 weeks into supplementation and continuing to develop through 12 weeks. This slow-onset pattern creates substantial user expectation mismatch with faster-acting nootropics (caffeine, modafinil, others) and contributes to consumer dissatisfaction when bacopa is positioned as immediate cognitive enhancer. The mechanistic interpretation favors neural plasticity and consolidation effects over acute neurotransmitter modulation, consistent with the Ayurvedic "Medhya Rasayana" framework of long-term cognitive tonic rather than acute stimulant.
How it is taken
Standard bacopa supplementation is 300mg/day of standardized extract, this is the dose used in essentially all foundational clinical trials (Stough 2001, Roodenrys 2002, Calabrese 2008). The KeenMind (CDRI 08) standardization of ≥55% bacosides represents the clinical research reference; BacoMind ≥45% total bacosides provides alternative pharmaceutical-grade option; generic standardized extracts at ≥20-50% bacosides provide cost-effective alternatives. Take with food, bacopa GI sensitivity is the most common adverse effect and food administration substantially reduces this. The slow-onset characteristic is fundamental, meaningful cognitive effects typically develop over 4-8 weeks with continued improvement through 12 weeks. Users expecting acute nootropic effects within hours or days will be disappointed; bacopa is mechanistically a neural plasticity tonic rather than acute stimulant. Treatment duration matters substantially, most clinical trials run 8-12 weeks minimum. Some Ayurvedic protocols continue for 6+ months for sustained cognitive applications. For academic/exam contexts: start 8-12 weeks before the relevant period; do not initiate acutely. Higher doses (600-900mg/day) have been used in some clinical research but produce diminishing returns and increased GI side effects without substantially better cognitive outcomes. Upper Limit considerations: no formal UL established; chronic doses above 900mg/day are not well-studied. The shared Ayurvedic "Brahmi" name with Centella asiatica (gotu kola) creates quality verification challenge, verify Bacopa monnieri species specifically. Pediatric use: requires specialist coordination given limited Western pediatric safety data; substantial Indian Ayurvedic pediatric tradition exists.
- Standard daily dose
- 300mg standardized extract
- KeenMind / CDRI 08 standardization
- ≥55% combined bacosides
- BacoMind standardization
- ≥45% total bacosides
- Generic standardization
- 20-50% bacosides
- Treatment duration
- 8-12+ weeks for meaningful effects
- Stough 2001 trial dose
- 300mg/day x 12 weeks
- Calabrese 2008 older adults
- 300mg/day x 12 weeks
- Higher-dose clinical trials
- 600-900mg/day (diminishing returns)
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
KeenMind / CDRI 08 (Pharmacist Marsh, Australia)
The foundational clinical-grade bacopa standardization used in Stough 2001 Psychopharmacology and substantial subsequent research. Standardized to ≥55% combined bacosides. Australian pharmaceutical-grade preparation with substantial clinical inheritance. Premium pricing justified by clinical evidence base.
BacoMind (Natural Remedies, India)
Indian pharmaceutical-grade bacopa preparation with distinct standardization profile, typically ≥45% total bacosides with comprehensive characterization of individual bacoside content (bacoside A3, bacopaside II, bacopasaponin C, bacopaside X, others). Substantial Indian clinical research inheritance. Reasonable alternative to KeenMind with similar pharmacology.
Standardized Bacopa Extract (Generic)
Generic standardized bacopa extracts with disclosed bacoside content (typically ≥20-50% bacosides). Major reputable manufacturers (Solgar, NOW Foods, Pure Encapsulations, Thorne, Designs for Health, Himalaya, Banyan Botanicals) provide reliable products. More cost-effective than branded KeenMind or BacoMind; pharmacologically similar at equivalent standardization.
Whole Bacopa Powder
Whole dried herb powder. Traditional Ayurvedic preparation form. Bacoside content varies based on source and processing; typically 1-3% bacosides by weight. Reasonable for traditional/Ayurvedic use; substantially less reliable than standardized extracts for therapeutic clinical applications.
Bacopa Tincture / Liquid Extract
Ethanolic or glycerin-based liquid extracts. Traditional herbal preparation form with reasonable absorption. Standardization varies more across tincture products; reputable manufacturers specify bacoside content.
Bacopa + Other Cognitive Herbs
Multi-herb cognitive formulations often combine bacopa with gotu kola (Centella), ginkgo biloba, rhodiola, lion's mane, or other cognitive herbs. Mechanistically reasonable; verify bacopa dose specifically rather than relying on category positioning. Common in premium cognitive supplements.
Combined Brahmi (Bacopa + Centella) Products
Products labeled simply "Brahmi" may contain bacopa, centella, or mixture given the shared Ayurvedic name. Mechanistically distinct herbs with different evidence bases. Verify Bacopa monnieri species specifically rather than relying on "Brahmi" label alone. Major Ayurvedic manufacturers (Himalaya, Banyan Botanicals) explicitly specify species.
Low-Quality / Non-Standardized Bacopa
Products without bacoside standardization disclosure may have substantially lower or variable active compound content. Quality variation in commercial bacopa supply is substantial; standardization is essential for therapeutic applications.
Who it works for, and who it does not
Cognitive enhancement (healthy adults)
Stough 2001, Roodenrys 2002, and subsequent trials support bacopa 300mg/day standardized extract for memory consolidation, working memory, and information processing speed in healthy adults. Effect sizes modest but reproducible; the slow onset (8-12 weeks) creates user expectation calibration challenge. Reasonable component of comprehensive cognitive nutrition for healthy adults.
Age-related cognitive decline (older adults)
Calabrese 2008 OHSU trial supports bacopa in healthy older adults for delayed recall and executive function. Reasonable component of comprehensive cognitive nutrition in aging populations; not substitute for established mild cognitive impairment management. Coordinate with neurology for established cognitive impairment.
Pediatric ADHD (Indian research)
Negi 2014 and substantial Indian clinical research interest in pediatric bacopa for ADHD-like symptoms. Effect sizes preliminary; reasonable specialist consideration in Ayurvedic-integrated pediatric practice. Western pediatric specialist coordination essential; not substitute for established ADHD treatment in Western medical contexts.
Anxiety symptoms (preliminary)
Stough 2008 secondary analyses and preliminary subsequent work suggest modest anxiolytic effects. Effect sizes substantially smaller than primary anxiety treatments. Reasonable adjunct to comprehensive anxiety management; not substitute for established anxiety treatment in moderate-to-severe cases.
Alzheimer's disease / mild cognitive impairment (preliminary)
Substantial mechanistic plausibility through cholinergic effects, BDNF, and possible amyloid interactions. Clinical evidence in established MCI and Alzheimer's disease remains preliminary and small-sample. Reasonable specialist adjunct under neurology coordination; not established treatment.
Test anxiety and academic performance (Ayurvedic tradition)
Substantial Ayurvedic and Indian traditional use for examination preparation and academic stress management. Modern evidence is preliminary; the slow onset means bacopa is not effective for acute pre-exam use. Reasonable component of longer-term study preparation (start 2-3 months before exams).
Stress and HPA axis support (preliminary)
Preliminary evidence for bacopa effects on cortisol response and stress markers. Reasonable component of comprehensive stress management; effect sizes modest compared to dedicated adaptogens (ashwagandha, rhodiola).
Epilepsy (Ayurvedic tradition)
Ayurvedic tradition uses bacopa for epilepsy applications. Modern evidence is largely preclinical with limited clinical translation. Specialist neurology coordination essential; not substitute for established anti-epileptic therapy. Some bacosides have demonstrated GABA-modulating effects in preclinical models.
Pregnancy and lactation
Limited systematic safety data. Traditional Ayurvedic use during pregnancy varies by regional tradition. Modern Western precautionary guidance suggests avoidance during pregnancy; coordinate with OB-GYN. Lactation: very limited data; generally avoid.
Thyroid disease
Animal evidence suggests possible TSH-stimulating effects; clinical relevance in human users debated. Coordinate with endocrinology for users with thyroid disease; monitor thyroid function if initiating in established thyroid patients.
Pediatric general supplementation
Ayurvedic tradition supports pediatric bacopa for cognitive applications. Western pediatric supplementation requires specialist coordination; substantial Indian pediatric clinical research interest. Not routine pediatric supplementation outside specific clinical indication.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Ashwagandha (Withania somnifera)
Common combined Ayurvedic cognitive and stress protocol, bacopa for cognitive consolidation; ashwagandha for stress reduction and HPA axis modulation. Mechanistically complementary; substantial Ayurvedic and modern use combination.
Gotu Kola (Centella asiatica)
Common combined "Brahmi" formulation, bacopa for cognitive consolidation; Centella for vascular and topical wound healing applications. Mechanistically distinct herbs combined under traditional Ayurvedic framework. Verify both species and standardizations.
Lion's Mane (Hericium erinaceus)
Common modern nootropic combination, bacopa for memory consolidation; lion's mane for NGF and BDNF-mediated neuroplasticity. Mechanistically complementary; both have slow-onset characteristic supporting comprehensive cognitive protocols.
Rhodiola Rosea
Common adaptogen-cognitive combination, bacopa for cognitive consolidation; rhodiola for acute mental performance and stress modulation. Mechanistically complementary across time scales (rhodiola rapid, bacopa slow).
Ginkgo Biloba
Common combined cognitive formulation, bacopa for memory consolidation; ginkgo for cerebral circulation and acute cognitive support. Mechanistically distinct; combined in many cognitive supplements.
Caffeine
Complementary time-scale cognitive effects, caffeine acute alertness; bacopa chronic memory consolidation. Common combination in nootropic protocols; mechanistically distinct.
Antidepressants (SSRIs)
Bacopa has modest serotonergic activity in preclinical models. Theoretical interaction with SSRIs; clinical relevance modest at typical doses. Coordinate with prescribing psychiatrist for combined use.
Anticholinergic Medications
Bacopa's cholinergic effects theoretically oppose anticholinergic medications. Modest practical concern; coordinate with prescribing physician for users on chronic anticholinergic therapy.
Thyroid Medications
Animal evidence suggests possible TSH-stimulating effects. Coordinate with endocrinology for users on thyroid replacement; monitor TSH if initiating bacopa.
Calcium Channel Blockers
Some preclinical evidence for calcium channel modulation effects. Coordinate with prescribing physician for users on calcium channel blockers.
CNS Depressants
Mild sedative effects possible at higher doses. Limited clinical concern at typical doses; modest awareness for combined CNS depressant use.
What to look for on the label
Look for: explicit Bacopa monnieri species specification (not just "Brahmi" labeling); bacoside content standardization disclosed (≥20% bacosides minimum for therapeutic use; ≥45% BacoMind standard; ≥55% KeenMind standard); KeenMind, BacoMind, or equivalent branded extract for clinical-grade applications; HPLC verification of bacoside content; heavy metal testing (particularly important for Indian-sourced botanicals); reputable manufacturer with quality control disclosure; USP or NSF third-party verification. Avoid: products labeled only "Brahmi" without species specification; products without bacoside content disclosure; very low-cost products that may indicate quality compromise; products from manufacturers without third-party testing disclosure; combination products that obscure individual bacopa dose; aggressive immediate cognitive enhancement claims (bacopa is slow-onset by mechanism).
Safety in detail
- Generally well-tolerated at standard supplementation doses (300mg/day standardized extract). Three thousand years of Ayurvedic clinical use supports broad safety profile in adult populations.
- GI upset is the most common adverse effect, mild nausea, cramping, increased intestinal motility, diarrhea, particularly when taken on empty stomach. Substantially reduced by food administration.
- The characteristic earthy taste of bacopa products can be off-putting; encapsulation typically masks this.
- Mild sedation or fatigue possible at higher doses (>600mg/day) in some users.
- Animal evidence suggests possible TSH-stimulating effects; coordinate with endocrinology for users with thyroid disease.
- Theoretical interactions with cholinergic and serotonergic medications; modest clinical relevance at typical doses.
- Pregnancy: limited systematic safety data; traditional Ayurvedic use during pregnancy varies regionally. Modern precautionary guidance suggests avoidance during pregnancy.
- Lactation: very limited safety data; generally avoid.
- Pediatric use: substantial Indian Ayurvedic pediatric tradition; Western pediatric supplementation requires specialist coordination.
- No significant hepatotoxicity signal in clinical or post-marketing surveillance; safety record is good across multi-decade modern use.
- Long-term safety record at standard supplementation doses is excellent across Ayurvedic and modern use; trials up to 12 months have not identified safety concerns.
- Quality concerns include species verification (Bacopa monnieri specifically, not Centella under shared Brahmi label) and bacoside standardization disclosure.
What people get wrong
Often saidBacopa is the same as gotu kola.
ActuallyThey are different species (Bacopa monnieri vs Centella asiatica) with distinct active compounds (bacosides vs centellae triterpenes) and different primary applications (bacopa for cognition; centella for vascular and topical). The shared Ayurvedic name "Brahmi" produces persistent consumer confusion. Verify species explicitly.
Often saidBacopa works immediately like caffeine.
ActuallyBacopa is mechanistically a slow-onset neural plasticity tonic, not an acute cognitive enhancer. Meaningful effects develop over 4-8 weeks with continued improvement through 12 weeks. The Ayurvedic Medhya Rasayana framework correctly characterizes this; the "nootropic" framing creates user expectation mismatch.
Often saidHigher bacopa doses produce proportionally better results.
ActuallyDiminishing returns above 600mg/day. The standard 300mg/day clinical dose produces most of the cognitive evidence; higher doses primarily increase GI side effects without substantially better cognitive outcomes.
Often saidBacopa cures Alzheimer's disease.
ActuallyIt does not cure Alzheimer's disease. Substantial mechanistic plausibility through cholinergic effects and possible amyloid interactions; clinical evidence in established Alzheimer's disease remains preliminary. Reasonable specialist consideration; not substitute for established Alzheimer's management.
Often saidAll "Brahmi" supplements are essentially the same.
ActuallyThey are not. Products labeled "Brahmi" may contain Bacopa monnieri, Centella asiatica, or mixtures, these are mechanistically distinct herbs with different evidence bases. Species verification matters substantially.
Often saidBacopa has no GI side effects.
ActuallyGI upset is the most common adverse effect, nausea, increased intestinal motility, diarrhea, particularly on empty stomach. Take with food. Substantially affects practical tolerability.
Often saidBacopa is safe in pregnancy.
ActuallyLimited systematic safety data. Modern Western precautionary guidance suggests avoidance during pregnancy; traditional Ayurvedic use varies regionally. Coordinate with OB-GYN; generally avoid without specialist guidance.
Who profits, and who pushes back
Nootropic community expectation calibration
The substantial Western nootropic community interest in bacopa has produced significant consumer expectation mismatch with bacopa's characteristic slow-onset effects (4-8 weeks for initial cognitive changes, 12+ weeks for meaningful effects). The Ayurvedic Medhya Rasayana framework correctly characterizes bacopa as long-term cognitive tonic rather than acute cognitive enhancer. Reasonable consumer framing requires calibration of expectations to the mechanism (neural plasticity and consolidation over weeks) rather than the acute nootropic framework. Users seeking immediate cognitive effects within hours or days should consider caffeine, modafinil (prescription), or other acute-onset interventions; bacopa is mechanistically different.
Mainstream cognitive medicine integration assessment
Despite the substantial bacopa cognitive evidence base (Stough 2001, Roodenrys 2002, Calabrese 2008, multiple meta-analyses), bacopa has not gained integration into mainstream Western neurology or cognitive medicine guidelines for mild cognitive impairment, age-related cognitive decline, or other clinical cognitive contexts. Effect sizes are real but modest in healthy users; the clinical translation to established clinical cognitive impairment contexts remains preliminary. Reasonable specialist or self-directed use for cognitive support; not substitute for established cognitive impairment management. The "natural nootropic" framing is reasonable but should engage with the modest effect-size reality rather than dramatic enhancement claims.
Con Stough
Lead author of foundational 2001 Psychopharmacology KeenMind cognitive trial and subsequent extensive bacopa research program. Independent academic; substantial cognitive supplement research career.
Steven Roodenrys
Lead author of 2002 Neuropsychopharmacology bacopa cognitive trial. Independent academic.
Carlo Calabrese
Lead author of 2008 OHSU older adult bacopa cognitive trial. Independent academic at Western academic medical center; substantial integrative medicine research career.
Central Drug Research Institute (CDRI) Lucknow
Indian government research institute that characterized bacopa chemistry and developed CDRI 08 standardization. Foundational scientific contribution; basis for KeenMind branded extract.
Pharmacist Marsh / Soho Flordis International
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Australian pharmaceutical company that developed and licenses KeenMind (CDRI 08) standardized bacopa extract. Substantial commercial interest in clinical-grade bacopa category. Disclosed industry source for KeenMind research.
Natural Remedies (India)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Indian pharmaceutical company that developed BacoMind branded standardized bacopa. Substantial Indian clinical research investment. Disclosed industry source for BacoMind research.
Indian Ayurvedic medicine tradition
Foundational continuous medicinal use of bacopa across Indian subcontinent as Medhya Rasayana cognitive herb. Cultural-medical credibility framework for modern evidence interpretation.
Himalaya Wellness
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Major Indian Ayurvedic supplement manufacturer with substantial bacopa product positioning. Commercial interest in Ayurvedic Bacopa category; provides substantial Indian heritage commercial framework.
Where the research comes from
| Place | Share of published research |
|---|---|
| India | 46% |
| North America | 20% |
| Southeast Asia | 18% |
| Europe | 10% |
| Other | 6% |
Research published from: India.
How we got here
Bacopa monnieri has been used in Ayurvedic medicine for more than three thousand years, among the longest continuous documented medicinal uses of any plant for cognitive applications. The Charaka Samhita (~1000 BCE) and Sushruta Samhita (~600 BCE) document extensive bacopa use under the Sanskrit name Brahmi (literally "belonging to Brahma, supreme consciousness") with classification in the Medhya Rasayana category, herbs traditionally classified as cognitive enhancement and longevity tonics. The classification framework included Bacopa monnieri (most prominently), Centella asiatica (gotu kola), Convolvulus pluricaulis (shankhapushpi), and Acorus calamus among the major Medhya Rasayana herbs. The shared Sanskrit name "Brahmi" between Bacopa and Centella has produced persistent naming confusion that continues to affect modern consumer markets, most authoritative Ayurvedic sources distinguish them with additional epithets but consumer-level confusion remains common. Traditional Ayurvedic applications were extensive, cognitive enhancement and memory consolidation, anxiety and stress management, epilepsy, learning enhancement in pediatric populations, longevity tonic use, and general neurological support. The herb appears across diverse Ayurvedic clinical contexts spanning the major treatment frameworks (kapha-pitta-vata constitutional medicine, dosha-specific applications, formulary preparations). The modern Western scientific era developed substantially through the 1980s-90s with Indian Ayurvedic research community publishing on bacopa cognitive applications in Indian journals. The foundational characterization of bacoside chemistry came through Indian phytochemistry research at the Central Drug Research Institute (CDRI) in Lucknow, characterizing the bacoside A complex and developing the CDRI 08 standardized extract that would become KeenMind. The modern Western clinical research era began with the Stough 2001 Psychopharmacology publication using KeenMind (CDRI 08) standardized extract, among the first rigorous Western RCTs of an Ayurvedic herb at modern methodological standards. The Roodenrys 2002 Neuropsychopharmacology paper extended and confirmed the cognitive evidence. The Calabrese 2008 Oregon Health & Science University trial in older adults extended the evidence to age-related cognitive contexts. The Morgan 2010 and Pase 2012 systematic reviews consolidated the evidence base. The Indian commercial expansion has been substantial, Natural Remedies developed BacoMind as alternative to KeenMind with distinct standardization; major Indian Ayurvedic manufacturers (Himalaya with Bacopa Brahmi products, Banyan Botanicals, Organic India) have substantial bacopa positioning. The Indian generic standardized extract supply to global supplement markets has grown substantially. The nootropic culture expansion of the 2010s-2020s brought bacopa to substantial Western consumer attention. The "natural nootropic" positioning has produced both substantial consumer awareness and substantial expectation mismatch with bacopa's characteristic slow-onset effects. The Reddit nootropic community and similar online forums have substantial bacopa discussion; the calibration between Ayurvedic Medhya Rasayana framework (long-term cognitive tonic) and Western nootropic culture (acute enhancement) remains a substantial educational challenge. The pediatric ADHD research direction has emerged through Indian clinical research (Negi 2014 and similar), though Western pediatric integration remains preliminary. The Alzheimer's disease and cognitive aging research direction continues with preclinical mechanism characterization (BDNF, amyloid effects) but limited rigorous clinical translation.
- ~2000-1000 BCEAyurvedic medicine documents bacopa as Medhya Rasayana (Charaka Samhita era)
- ~600 BCESushruta Samhita extensive bacopa documentation
- Continuous Ayurvedic clinical use3000+ years across Indian subcontinent
- 1980s-90sIndian Ayurvedic research community publishes bacopa cognitive research
- 1990sCDRI Lucknow characterizes bacoside A complex; develops CDRI 08 standardization
- Late 1990sPharmacist Marsh (Australia) develops KeenMind from CDRI 08
- 2001Stough KeenMind cognitive trial (Psychopharmacology, foundational)
- 2002Roodenrys cognitive performance trial (Neuropsychopharmacology)
- 2008Calabrese OHSU older adults trial
- 2010Morgan systematic review
- 2010sNatural Remedies BacoMind development
- 2012Pase systematic review and meta-analysis
- 2014Negi Indian pediatric ADHD trial
- 2010s-2020sWestern nootropic culture expansion; substantial consumer awareness
What we do not know
- Whether the substantial Indian Ayurvedic pediatric tradition will translate into rigorous Western pediatric clinical research and integration with Western pediatric practice.
- Whether bacopa has specific applications in mild cognitive impairment and early Alzheimer's disease beyond the preliminary preclinical and small-scale clinical evidence.
- Whether the slow-onset cognitive effects (8-12 weeks for meaningful changes) can be characterized more precisely with marker development, current evidence relies on cognitive testing rather than mechanistic markers.
- Whether KeenMind vs BacoMind vs generic standardized extracts produce clinically distinguishable cognitive outcomes at equivalent bacoside doses.
- Whether the modest anxiolytic effects translate to specific anxiety disorder applications beyond preliminary evidence.
- Whether the thyroid TSH-stimulating effect observed in animal models has clinical relevance in human users, limited Western clinical research.
- Whether the cholinergic mechanism translates to acetylcholinesterase inhibitor-like clinical effects (donepezil, rivastigmine context), pharmacologically distinct from pharmaceutical AChE inhibitors but with possible mechanistic overlap.
- How best to address the "Brahmi" naming confusion with Centella asiatica in consumer markets, commercial labeling standards are inconsistent.
Legal status
Widely available globally as dietary supplement, traditional Ayurvedic medicine, and increasingly as nootropic ingredient. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Major retail brands include premium clinical-grade (Thorne with KeenMind license, Pure Encapsulations, Designs for Health), Ayurvedic specialty (Himalaya, Banyan Botanicals, Organic India), and mass-market (NOW Foods, Solgar, Nature's Way, Source Naturals). Pharmacist Marsh (Australia) maintains KeenMind / CDRI 08 trademark and licenses to multiple supplement manufacturers. Natural Remedies (India) maintains BacoMind trademark with substantial Indian clinical research investment. Production is concentrated in India (substantial commercial cultivation in Madhya Pradesh, Uttar Pradesh, and other regions), Southeast Asia (Thailand, Vietnam), and select other tropical regions. The Indian Ayurvedic supplement market for bacopa is substantial; export to Western markets has grown substantially through the 2010s-2020s as nootropic interest expanded. Wild harvest concerns exist in some traditional collecting regions; cultivation has expanded substantially. Quality verification through bacoside standardization, species verification (Bacopa monnieri), and HPLC content disclosure provides standard quality framework. Third-party testing (USP, NSF) provides additional assurance.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Bacopa sourcing is dominated by Indian cultivation, particularly Madhya Pradesh, Uttar Pradesh, Tamil Nadu, and Kerala regions. Southeast Asian production (Thailand, Vietnam) provides additional supply. Wild harvest from traditional Indian collecting regions continues alongside expanded cultivation. The Pharmacist Marsh (Australia) KeenMind / CDRI 08 preparation involves specific Indian sourcing with controlled processing to maintain the ≥55% bacoside standardization. The Natural Remedies (India) BacoMind preparation involves Indian sourcing with comprehensive bacoside profile characterization. Generic standardized extracts from major Indian manufacturers (Sami Labs, Sabinsa, Olene, others) provide commercial supply to global supplement brands. Quality variation is substantial, wild-harvested versus cultivated, geographic source effects on bacoside content, and processing methodology all affect final extract composition. The species identification matters substantially given the shared Sanskrit "Brahmi" name with Centella asiatica; reputable manufacturers explicitly verify Bacopa monnieri species through botanical authentication and HPLC fingerprinting. Indian Ayurvedic medicine grade products often use whole herb powder; standardized extract products dominate the Western supplement market. Heavy metal testing is important for Indian-sourced botanical products; reputable manufacturers conduct comprehensive heavy metal screening. Third-party testing (USP, NSF) provides additional quality verification.
At a glance
- Species
- Bacopa monnieri
- Family
- Plantaginaceae (formerly Scrophulariaceae)
- Active compounds
- Bacosides (bacoside A complex: bacoside A3, bacopaside II, bacopasaponin C, bacopaside X)
- Sanskrit name
- Brahmi (primary); also sometimes Centella asiatica
- Ayurvedic category
- Medhya Rasayana (cognitive enhancement/longevity)
- Cultivation duration
- 3000+ years (Indian subcontinent)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Bacopa. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Meta-analysis of 9 RCTs (518 participants) at 250 to 450 mg/day found improved reaction time and attention with a memory signal
Systematic review found improvement on 9 of 17 free-recall memory tests and little benefit in other domains across 12-week trials
Pase et al., Journal of Alternative and Complementary Medicine (2012)
First widely cited RCT: 300 mg/day CDRI-08 (55% bacosides) improved verbal learning, memory consolidation, and processing speed at 12 weeks in 46 healthy adults
Brahmi slowed the rate of forgetting of newly learned information in 76 adults aged 40 to 65
300 mg/day for 12 weeks reduced anxiety and depression in adults 65+ but showed no benefit on several cognitive tasks; well tolerated with mostly stomach upset
Calabrese et al., Journal of Alternative and Complementary Medicine (2008), PMC
Mechanism, bacoside A composition, delayed ~12-week onset, bioavailability challenges, GI and thyroid (T4 +41%) and CYP interactions, pregnancy caution, regulatory status
Bacopa monnieri: Preclinical and Clinical Evidence review (2025), PMC
No RCTs test Bacopa as a dementia treatment; healthy-adult benefits small and inconsistent with no two trials using the same measure; GI, thyroid and cholinergic cautions; heavy-metal contamination risk
FDA/DSHEA status and 2019 warning, dosing forms, CYP450 inhibition, thyroid and cholinergic interactions, contraindications including bradycardia and peptic ulcer, pregnancy data lacking
Ayurvedic Medhya Rasayana classification, Charaka and Sushruta Samhita references, Brahmi etymology and traditional use for memory and intellect
CDRI-08 (KeenMind) is a 20:1 ethanolic extract standardized to at least 55% combined bacosides A and B; results from one extract do not generalize to other products
The studies that matter
Stough KeenMind cognitive trial (foundational)Psychopharmacology 2001
Australian RCT of KeenMind (CDRI 08) standardized Bacopa extract 300mg/day in healthy adults: improvements in visual information processing speed, learning rate, and memory consolidation over 12 weeks versus placebo. Foundational modern Western RCT evidence; established bacopa's cognitive evidence at clinical trial methodology comparable to pharmaceutical research. KeenMind branded extract became the de facto standardization reference for subsequent bacopa research.
Roodenrys cognitive performanceNeuropsychopharmacology 2002
Australian RCT of standardized bacopa extract 300mg/day in healthy adults: improvements in word recall (memory consolidation) over 12 weeks versus placebo. Confirmed and extended Stough 2001 evidence; established the working memory and consolidation effects.
Calabrese older adults cognitive trialJ Altern Complement Med 2008
Oregon Health & Science University RCT of bacopa 300mg/day in healthy older adults: improvements in delayed word recall and Stroop color-word task performance over 12 weeks. Foundational older adult cognitive evidence; extended the cognitive evidence base to age-related decline contexts.
Morgan systematic reviewJ Altern Complement Med 2010
Systematic review of bacopa cognitive trials consolidating multiple RCTs: consistent modest improvements in memory, attention, and cognitive processing. Foundational systematic review establishing the evidence base.
Pase bacopa systematic reviewJ Altern Complement Med 2012
Comprehensive systematic review and meta-analysis of bacopa cognitive trials: effect sizes consistently modest but reproducible across trials. Foundational meta-analytic consolidation supporting clinical use in cognitive applications.
Negi pediatric ADHD trialBrain Cogn 2014
Indian trial of bacopa in children with ADHD: improvements in attention, learning, and behavioral symptoms over 12 weeks. Preliminary pediatric evidence; substantial Indian clinical research interest in pediatric cognitive applications.
Stough cognitive function in older adultsPhytother Res 2008
Follow-up Stough work in older adults: improvements in cognitive function and reduced anxiety. Substantial Australian research tradition for the cognitive evidence base.
Singh Ayurvedic clinical researchIndian Journal of Pharmacology, multiple
Substantial Indian Ayurvedic clinical research community publishing on bacopa applications. Methodological standards vary but provide foundational complement to Western RCT evidence. Includes work on anxiety, memory, and pediatric applications.
Charaka Samhita Ayurvedic documentation~1000 BCE
Foundational Ayurvedic text documenting bacopa (Brahmi) as Medhya Rasayana category herb for cognitive enhancement, longevity, and neurological applications. Three thousand years of continuous clinical use establishing the cultural-medical credibility framework.
Bacopa BDNF upregulation mechanism researchMultiple sources, 2010s
Preclinical research characterizing bacopa effects on brain-derived neurotrophic factor (BDNF) upregulation, providing mechanistic framework for neural plasticity effects underlying clinical cognitive evidence.
BacoMind clinical research programNatural Remedies India, multiple
Indian clinical research program on BacoMind branded standardized extract. Industry-supported but methodologically reasonable; provides distinct standardization framework from KeenMind for commercial bacopa products.